← Back to Screener
Mesoblast Limited American Depositary Shares (MESO)
Price$14.86
Value ScoreD
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-25.37%
Price vs S&P 500 (4W)-8.18%
VGM Score49.82
Market Capitalization$2.77B
All Metrics
Book Value / Share (Quarterly)$0.45
P/TBV (Annual)9.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.97%
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)-32.40%
Gross Margin (TTM)57.98%
Net Profit Margin (TTM)-144.33%
EPS (TTM)$-0.07
10-Day Avg Trading Volume2.21M
EPS Excl Extra (TTM)$-0.07
Revenue Growth (5Y)-11.76%
EPS (Annual)$-0.08
ROI (Annual)-14.08%
Gross Margin (Annual)70.17%
Net Profit Margin (5Y Avg)-1079.10%
Cash / Share (Quarterly)$0.10
Revenue Growth QoQ (YoY)1526.81%
ROA (Last FY)-13.02%
Revenue Growth TTM (YoY)1053.16%
EBITD / Share (TTM)$-0.06
ROE (5Y Avg)-17.42%
Operating Margin (TTM)-115.66%
Cash Flow / Share (Annual)$-0.04
P/B Ratio3.46x
P/B Ratio (Quarterly)4.48x
Net Income / Employee (Annual)$-1,261,000
EV / Revenue (TTM)30.48x
Net Interest Coverage (TTM)-4.56x
ROA (TTM)-12.04%
EPS Incl Extra (Annual)$-0.08
Current Ratio (Annual)1.99x
Quick Ratio (Quarterly)1.35x
3-Month Avg Trading Volume3.45M
52-Week Price Return21.26%
Revenue / Employee (TTM)$807,200
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)115.54x
Asset Turnover (Annual)0.02x
52-Week High$3.31
Operating Margin (5Y Avg)-873.47%
EPS Excl Extra (Annual)$-0.08
CapEx CAGR (5Y)-20.16%
Tangible BV CAGR (5Y)9.39%
26-Week Price Return-9.44%
Quick Ratio (Annual)1.72x
13-Week Price Return-5.80%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)1.58x
Enterprise Value$1.99B
Revenue / Share Growth (5Y)-25.24%
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)-13.18%
Revenue / Employee (Annual)$212,300
Pretax Margin (Annual)-592.00%
Cash / Share (Annual)$0.13
3-Month Return Std Dev56.24%
Gross Margin (5Y Avg)-181.16%
Net Income / Employee (TTM)$-1,165,100
ROE (Last FY)-17.10%
Net Interest Coverage (Annual)-5.06x
EPS Basic Excl Extra (Annual)$-0.08
Receivables Turnover (TTM)2.95x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-0.07
Receivables Turnover (Annual)2.25x
ROI (TTM)-13.15%
P/S Ratio (TTM)30.39x
Pretax Margin (5Y Avg)-1082.59%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)-6.94%
Year-to-Date Return-22.43%
5-Day Price Return1.44%
EPS Normalized (Annual)$-0.08
ROA (5Y Avg)-13.09%
Net Profit Margin (Annual)-593.92%
Month-to-Date Return-1.40%
Cash Flow / Share (TTM)$-0.16
EBITD / Share (Annual)$-0.07
Operating Margin (Annual)-480.93%
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-14.30%
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$-0.07
P/TBV (Quarterly)18.36x
P/B Ratio (Annual)2.54x
Pretax Margin (TTM)-143.47%
Book Value / Share (Annual)$0.47
Price vs S&P 500 (13W)-15.55%
Beta1.82x
P/FCF (Annual)18.71x
Revenue / Share (TTM)$0.05
ROE (TTM)-16.10%
52-Week Low$1.53
vGradeD
gGradeB
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MESOMesoblast Limited American Depositary Shares | D | B | C | $14.86 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Mesoblast is a commercial-stage biotechnology company developing allogeneic cellular medicines for serious inflammatory and degenerative diseases. Key programs include Ryoncil for steroid-refractory acute graft-versus-host disease and acute respiratory distress syndrome, Revascor for chronic heart failure, and a candidate for chronic low back pain. The company leverages a proprietary adult stem cell technology platform designed for off-the-shelf therapeutic applications.